Literature DB >> 27480143

An unusual and malignant intussusception in a child.

Gabriella D'Angelo1,2,3, Lucia Marseglia4,5, Marta Manti6, Giovanni Stroscio6, Daniela Impollonia6, Salvatore Arena7, Pietro Impellizzeri7, Carmelo Salpietro6, Carmelo Romeo7, Eloisa Gitto4,5.   

Abstract

Intussusception is a common cause of bowel obstruction in the pediatric population. Malignant lesions account for up to 30 % of all cases of intussusception in the small intestine. We herein report an interesting case of ileo-colic intussusception caused by diffuse large B-cell lymphoma, in a child. The patient underwent laparoscopic right hemicolectomy. Pathologic evaluation revealed a diffuse large B-cell lymphoma.In cases of intussusception, especially in the older age group of children, a high index of suspicion for malignant lymphoma of the bowel should be observed.

Entities:  

Keywords:  Bowel obstruction; Child; Malignant tumour; Small intestine; Surgery

Mesh:

Year:  2016        PMID: 27480143      PMCID: PMC4970252          DOI: 10.1186/s13052-016-0283-2

Source DB:  PubMed          Journal:  Ital J Pediatr        ISSN: 1720-8424            Impact factor:   2.638


Dear editor

Intussusception, defined as the telescoping of a segment of the gastrointestinal tract into an adjacent one, is often seen in paediatric age [1]. Gastrointestinal tumours, especially if they occur in the large bowel, cause intestinal intussusception in 63–68 % of cases [2]. Intussusception caused by diffuse large B-cell lymphoma (DLBCL), as a cause of acute abdomen, is rare, and, often, intussusception represents the first clinical sign, leading, potentially, to disease detection at an early stage [3]. We herein present a rare case of an ileo-colic intussusception caused by DLBCL in a pediatric patient who initially underwent surgical treatment and, subsequently, adjuvant chemotherapy. An 8-year-old boy presented with previous medical history of abdominal pain and nausea with vomiting following meals. Symptoms progressively worsened to severe anorexia, weight loss, constipation, and bilious vomiting, on the day of admission. Fever, chills, bleeding per rectum, and previous abdominal surgeries were absent. Laboratory tests only showed increased C-reactive protein (2.5 mg/L, normal range 0–0.5 mg/L). Abdominal X-ray revealed no specific bowel gas pattern, but with gaseous distension of several small bowel loops. Focused sonography of the right lower quadrant reported a “target sign” or “doughnut”, pseudokidney/sandwich appearance [Fig. 1], suggesting bowel intussusception. Abdominal computed tomography (CT) revealed a typical target-appearing lesion, extending for approximately 16 cm of the terminal ileum and ascending colon into the transverse colon. Liver metastasis was also described. Emergency laparotomy confirmed a distal ileo-colic intussusception. Laparotomy was performed and an ileo-colic intussusception noted with a 4 cm × 4 cm intraluminal growth in the lumen, a large and hard mesenteric mass. Enlarged mesenteric lymph-nodes were also detected [Fig. 2]. The involved segment presented edema and initial necrosis with loss of the classic three-layer intestinal mucosa. It was resected with 5 cm margins, and end to end anastomosis was performed on the healthy small bowel. In the follow-up period, the patient underwent contrast enhanced CT scan of the thorax, abdomen and pelvis to look for synchronous lesions detected on admission (hepatic lesions). The child was thereafter referred to the Medical Oncology and Radiation Oncology Department where he underwent adjuvant chemotherapy and is under fortnightly follow-ups. The leading point of the invagination was a DLBCL measuring 4x4 cm, consisting of centroblastic/polymorphic cells of intermediate-large size; CD20+, CD10+, bcl2-, bcl6+, CD5-, D1, CKAE1-AE3, AML-. MIB > 70 %. All nodes showed reactive hyperplastic follicle-sinus histiocytosis and lymphostasis.
Fig. 1

Abdominal ultrasound noted an intussusception, giving the typical “target” sign

Fig. 2

Resected specimen showing the large B-cell lymphoma

Abdominal ultrasound noted an intussusception, giving the typical “target” sign Resected specimen showing the large B-cell lymphoma Primary malignant tumours of the small intestine are very rare, accounting for less than 2 % of all gastrointestinal malignancies [2]. Lymphoma constitutes 15–20 % of all small intestine neoplasms [4]. In particular, DLBCL, the most common form of non-Hodgkin lymphoma (NHL), is a heterogeneous entity rarely causing acute obstructive symptoms and intussusceptions [5]. Intestinal involvement of NHL has been correlated to increased frequency of abdominal symptoms resulting in an earlier diagnosis. It was found that the invasion depth of the tumour is significantly associated with patient survival [6]. DLBCL-patients initially undergo chemotherapy rather than surgery. Therefore, the relationship between surgery treatment and prognosis has not previously been reported. The importance of resection of the bowel containing even the smallest of lesions, along with removal of regional lymph nodes, is further stressed [7]. Moreover, a multicenter study found that primary surgical resection was associated with a favourable prognosis in cases of intestinal DLBCL, encouraging surgical resection as primary treatment [8]. Conversely, an increased risk of gastric adenocarcinoma after treatment of primary gastric lymphoma has been also reported, especially of diffuse large B-cell lymphoma [9]. Finally, there is no consensus on the optimal treatment against primary gastrointestinal DLBC [5, 6]. In conclusion, we describe a pediatric case of large B-cell lymphoma causing an ileo-colic intussusception. In cases of intussusception, especially in the older age group of children, a high index of suspicion for malignant lymphoma of the bowel, including DLBCL should be observed.

Abbreviations

CT, computed tomography; DLBCL, diffuse large B-cell lymphoma; NHL, non-hodgkin lymphoma
  8 in total

1.  Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone.

Authors:  Seok Jin Kim; Hye Jin Kang; Jin Seok Kim; Sung Yong Oh; Chul Won Choi; Soon Il Lee; Jong Ho Won; Min Kyoung Kim; Jung Hye Kwon; Yeung-Chul Mun; Jae-Yong Kwak; Jung Mi Kwon; In Gyu Hwang; Hyo Jung Kim; Jinny Park; Sukjoong Oh; Jooryung Huh; Young Hyeh Ko; Cheolwon Suh; Won Seog Kim
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

2.  Pediatric management problems. Intussusception.

Authors:  Tina Simpson; Jean Ivey; Suzanne Borkowski
Journal:  Pediatr Nurs       Date:  2004 Jul-Aug

3.  Predictive factors of malignancy in adults with intussusception.

Authors:  Brian K P Goh; Hak-Mien Quah; Pierce K H Chow; Kok-Yang Tan; Khoon-Hean Tay; Kong-Weng Eu; London L P J Ooi; Wai-Keong Wong
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

Review 4.  Primary gastrointestinal lymphoma.

Authors:  Prasanna Ghimire; Guang-Yao Wu; Ling Zhu
Journal:  World J Gastroenterol       Date:  2011-02-14       Impact factor: 5.742

Review 5.  Unusual cause of adult intussusception: diffuse large B-cell non-Hodgkin's lymphoma: a case report and review.

Authors:  S Akbulut
Journal:  Eur Rev Med Pharmacol Sci       Date:  2012-12       Impact factor: 3.507

6.  Ileo-ileal intussusception caused by diffuse large B-cell lymphoma of the ileum.

Authors:  Xie-Qun Xu; Tao Hong; Bing-Lu Li; Wei Liu
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

7.  Intussusception in Children Aged Less than Five years.

Authors:  Sanjay Mehendale; C P Girish Kumar; S Venkatasubramanian; T Prasanna
Journal:  Indian J Pediatr       Date:  2016-05-23       Impact factor: 1.967

8.  Increased risk of gastric adenocarcinoma after treatment of primary gastric diffuse large B-cell lymphoma.

Authors:  Koji Inaba; Ryoji Kushima; Naoya Murakami; Yuuki Kuroda; Ken Harada; Mayuka Kitaguchi; Kotaro Yoshio; Shuhei Sekii; Kana Takahashi; Madoka Morota; Hiroshi Mayahara; Yoshinori Ito; Minako Sumi; Takashi Uno; Jun Itami
Journal:  BMC Cancer       Date:  2013-10-26       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.